Project Grant R01CA316361
- This federal Project Grant award of $399,829, awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports research to validate the use of positron emission tomography (PET) imaging to quantitatively measure the levels of the sphingosine-1-phosphate receptor 1 (S1PR1) in gastric tumors. The goal is to use this S1PR1-targeted PET imaging approach to predict and monitor the response of gastric tumors to antibody-drug conjugate...
- Summary The National Cancer Institute awarded The Methodist Hospital Research Institute a $415,257 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on June 9, 2026, to develop image-guided adaptable chimeric antigen receptor (CAR) T cell therapy for solid tumors. The project addresses critical limitations in current CAR T cell treatments, including tumor relapse, antigen escape, T cell exhaustion, and severe toxicities. The research will create a universal,...
- Federal Grant Award Summary Award Details: The National Cancer Institute (NCI) awarded Washington University a Project Grant of $645,414 on June 18, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394), with a project completion date of May 31, 2031. Products and Services: This award funds research translating mechanistic understanding of radiation-induced pulmonary fibrosis (RIPF) into novel clinical monitoring and treatment approaches. The project deliverables...
- Federal Grant Award Summary The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research a $452,540 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on July 11, 2025, with a completion date of June 30, 2027. This award supports the development of a novel T-cell imaging paradigm utilizing positron emission tomography (PET) agents targeting CD8 and CD4 markers to provide real-time monitoring of endogenous T-cell trafficking, tumor...
- Federal Project Grant Award Summary Thomas Jefferson University, operating as Sidney Kimmel Medical College, received a $802,230 Project Grant awarded on June 4, 2026, by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The award funds a two-year research initiative through May 31, 2028, focused on developing and validating microbubble-augmented neoadjuvant anti-programmed death-1 (APD1) immunotherapy for head and neck squamous cell...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Washington University a $641,419 Project Grant on May 7, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to support clinical translation and evaluation of a novel Meitner-Auger electron (MAE) emitter-based theranostic agent for metastatic castrate-resistant prostate cancer (MCRPC). The award funds development and first-in-man clinical imaging of [77BR]BR-WC-DZ, a stable bromine-77 ligand that...
- Grant Award Summary The National Cancer Institute (NCI) awarded The Washington University $645,323 under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on July 10, 2026, to optimize HER2-targeted therapy in HER2-low breast cancer patients. The project, which runs through June 30, 2031, will develop complementary biomarkers and therapeutic approaches to identify patients who respond to trastuzumab-deruxtecan (T-DXD), an antibody-drug conjugate (ADC), and overcome resistance...
- Federal Project Grant Award Summary The National Institute of Dental and Craniofacial Research (NIDCR) awarded a Project Grant totaling $427,625 to The Washington University (Office of Sponsored Research Services) effective February 6, 2026, through February 5, 2028, under the Oral Diseases and Disorders Research program (CFDA 93.121). The research project, titled "Radiation-Guided Theranostic Agents to Monitor Response to Oral Cancer Treatment," focuses on developing diagnostic and...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a Project Grant totaling $658,423 under the Cancer Biology Research program (CFDA 93.396) effective July 1, 2026 through June 30, 2031. This award supports fundamental research on therapeutic targeting of PI3K gamma (PI3Kγ)-positive tumor-associated macrophages (TAMs) in metastatic castration-resistant prostate cancer (MCRPC) to reduce health disparities. The research builds on the investigator...
- Federal Grant Award Summary The National Cancer Institute awarded a $399,829 Project Grant to The Washington University (Office of Sponsored Research Services) under the Cancer Treatment Research program (CFDA 93.395) for the period April 1, 2026, through March 31, 2028. This project focuses on the rational design of next-generation engineered T cells to enhance cancer immunotherapy by addressing a critical limitation in current chimeric antigen receptor (CAR) T cell treatments—limited...
Grant Summary: PET Imaging of CD163+ Tumor-Associated Macrophages in Head and Neck Cancer The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $623,616 Project Grant to The Washington University on July 10, 2026, with a completion date of June 30, 2031. This award funds research to develop and validate positron emission tomography (PET) imaging technology capable of non-invasively detecting and quantifying CD163-positive tumor-associated macrophages (TAMs) in head and neck squamous cell carcinoma (HNSCC). The project addresses a critical gap in cancer diagnostics by creating tools to visualize the spatiotemporal distribution of TAMs, which play a central role in tumor microenvironment composition and cancer progression. By targeting CD163 as a specific biomarker for TAMs, this research will enable clinicians and researchers to better understand immune cell involvement in tumorigenesis and predict therapeutic response. The research output will support improved cancer detection and diagnosis methodologies, consistent with NCI's strategic priorities in developing accurate diagnostic techniques and screening strategies to reduce cancer mortality. The project leverages Washington University's established research infrastructure and expertise in biomedical research, positioning the institution as a prime recipient capable of delivering novel molecular imaging agents and diagnostic protocols that could inform personalized treatment strategies for head and neck cancer patients and advance TAM-targeted immunotherapy development.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $623.6k | 7/10/26 |